The myoma vascularity study: Sonographic features of fibroids before and during non-surgical therapy and/or expectant management.

The myoma vascularity study: Sonographic features of fibroids before and during non-surgical therapy and/or expectant management. - MYOVASC

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50341

Enrollment

580

Registered

2018-09-20

Start date

2018-09-24

Completion date

Unknown

Last updated

2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fibroid myoma

Interventions

None listed

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - = 1 fibroid is accessible for transvaginal ultrasound) - Maximal diameter >=1.5 cm and

Exclusion criteria

Exclusion criteria: - Any fibroid treatment in the last 3 months in case of (3) SPRM e.g. Esmya or GnRH-analogues (except for exogenous hormone exposure) or (1) no treatment - Age

Design outcomes

Primary

Measure	Time frame
Volume reduction per study group after: 1. Natural behaviour - 1 year 2. Long-term exogenous hormonal exposure - 1 year 3. SPRMs e.g. Esmya or GnRH-analogues - 3 months 4. Initiation of exogenous hormonal exposure - 1 year 5. Embolization - 6 months 6. Ablation therapy - 6 months	—

Secondary

Measure	Time frame
All study groups: 1. UFS-Qol 2. EQ-5D score 3. PBAC-score 4. Haemoglobin level 5. Treatment failure rate 6. (Re)intervention rate	—

Countries

Netherlands

Outcome results